Visx attempts to deter raider with "poison pill" plan
This article was originally published in Clinica
Visx has set in place a takeover defence "poison pill" plan after financier Carl Icahn announced plans to buy a $15 million stake in the eye laser company, amounting to around 11% of outstanding shares.
You may also be interested in...
Despite seeing an 8% drop in global turnover in 2019, an upbeat Teva says the completion of its restructuring plan has positioned the company to increase its turnover through newly-launched products – including biosimilars, brands and new generics – as well as improve its profit margins through manufacturing optimization.
Japanese big pharma Eisai taps Celgene and Sanofi execs as its new VPs for corporate affairs and market access. And Freeline Therapeutics, developer of gene therapies for bleeding disorders, selects a former Alnylam Pharma SVP as CEO.